Key Highlights
- Croda International Plc (LSE:CRDA) returned to London's regulatory feed on 9 September with a Director/PDMR Shareholding notice, the kind of filing routinely read as insider buying and, in this instance, nothing of the sort.
- The substantive news came earlier, with results for the six months to 30 June published on 28 July. Sales reached 880.5 million pounds, up 4.6% organically and 2.9% as reported after currency headwinds, against 855.8 million a year earlier.
- Full-year guidance was left unchanged at the half year: group Organic Sales growth of 3 to 6%, with further adjusted Operating Margin expansion.
A share-scheme grant, not a vote of confidence
Croda International Plc (LSE:CRDA) returned to London's regulatory feed on 9 September with a Director/PDMR Shareholding notice, the kind of filing routinely read as insider buying and, in this instance, nothing of the sort.
The announcement records the grant of Options under the Croda International Plc Sharesave Scheme (2023) to two members of the executive committee. Sandra Elaine Breene received options over 118 shares and Thomas Hermann Riermeier over 207 shares, each at an option price of 26.37 pounds.
A Sharesave grant is an entitlement, not a purchase. No shares changed hands and no Capital was committed. Participants save a fixed monthly sum over a set term, then either exercise at the pre-agreed price or take their savings back. That price sits well below where Croda stock has traded recently: executives acquired shares under a separate all-employee arrangement at 3,292 pence in August.
A large holder heading the other way
The day before, Croda disclosed a notification with rather more substance. Norges Bank, which manages Norway's sovereign Wealth fund, reported a disposal of voting rights dealt on 7 September, reducing its interest from 7.9355% to 6.9548%, equivalent to 9,711,379 voting rights.
That is a reduction, not stake-building. Holdings notifications are triggered by threshold crossings rather than conviction, and a sovereign fund trims for reasons that need have nothing to do with a company's prospects. Still, the move came from one of the register's largest names.
Summer dealings pointed both ways
The preceding filings were similarly mixed. Group director Michelle Lydon sold 1,890 shares at 33.04 pounds on 31 July. Chief financial officer Stephen Oxley disposed of 1,339 shares at 32.14 pounds on 3 August in a tax-related transaction, the routine mechanism by which participants cover liabilities arising on share awards rather than a discretionary exit. On 10 August seven executives, including chief executive Steve Foots, each acquired five shares at 3,292 pence under an employee plan.
None of these is a conviction open-market purchase.
What the Business actually delivered
The substantive news came earlier, with results for the six months to 30 June published on 28 July. Sales reached 880.5 million pounds, up 4.6% organically and 2.9% as reported after currency headwinds, against 855.8 million a year earlier. Adjusted operating profit rose to 155.8 million pounds from 146.9 million, a 6.7% organic increase, lifting the adjusted operating margin to 17.7% from 17.2%.
Consumer Care did the heavy lifting, with sales of 523.7 million pounds and organic growth of 8.3%. Life Sciences was flat at 257.3 million pounds, up 0.2% organically, while Industrial Specialties slipped 1.9% to 99.5 million pounds and contributed just 4.0 million pounds of adjusted operating profit.
The Interim Dividend was held at 48.0 pence per share while the group rebuilds Earnings cover. Net Debt stood at 577.9 million pounds, Leverage at 1.4 times EBITDA within a 1 to 2 times target range, and free Cash Flow improved 36.8% to 38.3 million pounds.
Factors to watch
The tension is between a recovering Consumer Care business and a Life Sciences division that has stopped growing. Croda's margin story depends on mix, and a prolonged flat patch in pharmaceutical and crop-science ingredients would test it. Industrial Specialties remains a low-margin drag, and currency translation cut reported growth by more than a percentage point in the first half.
What comes next
Full-year guidance was left unchanged at the half year: group organic sales growth of 3 to 6%, with further adjusted operating margin expansion. The next milestone is the year-end trading update, and holders of the newly granted Sharesave options face no exercise decision for several years.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...